Yokoyama K, Shinohara N, Kondo M, Mashima T
Division of Orthopedic Surgery, National Kyushu Medical Center Hospital, Fukuoka.
Jpn J Clin Oncol. 1995 Aug;25(4):131-4.
The prognostic factors for synovial sarcoma were analyzed retrospectively in 18 patients. Variables evaluated for their use in predicting survival included the location of the primary tumor, tumor size, local recurrence, completeness of surgical resection, and histologic subtype. Chemotherapy was not evaluated because the patients received various regimens and/or inadequate doses. Tumor size was the most significant prognostic factor, and a diameter of more than 10 cm was associated with a significantly worse prognosis (risk ratio: 5.38) (P = 0.012). We conclude that complete surgical resection of tumors less than 5 cm in maximum diameter may be curative and that adjuvant chemotherapy may not be necessary for such patients, because the value of chemotherapy for synovial sarcoma is still controversial.
对18例滑膜肉瘤患者的预后因素进行了回顾性分析。评估用于预测生存的变量包括原发肿瘤的位置、肿瘤大小、局部复发、手术切除的完整性和组织学亚型。由于患者接受了不同的治疗方案和/或剂量不足,因此未对化疗进行评估。肿瘤大小是最重要的预后因素,直径超过10 cm与明显较差的预后相关(风险比:5.38)(P = 0.012)。我们得出结论,最大直径小于5 cm的肿瘤完整手术切除可能治愈,此类患者可能无需辅助化疗,因为化疗对滑膜肉瘤的价值仍存在争议。